Jiangxi Fushine Pharmaceutical Co Ltd. Stock Analysis 300497.SZ

Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi. The company went IPO on 2015-12-22. The firm mainly operates three businesses. The pharmaceutical manufacturing business is engaged in the production and sales of β-lactamase inhibitors, carbapenems (penicillin series) drugs, antiviral drug intermediates and other products. The lithium-ion battery industry chain-related business is engaged in the production and sales of lithium-ion battery electrolyte additives, including vinylene carbonate (VC) and fluoroethylene carbonate (FEC). The microbial protein business is engaged in the production and sales of yeast protein, microalgae protein and filamentous fungal protein. The firm conducts its business in the domestic and overseas markets.